Lineage Cell Therapeutics Inc., a clinical-stage biotechnology company, has announced the launch of a new islet cell transplant program targeting Type 1 Diabetes (T1D). The initiative aims to leverage the company's manufacturing capabilities to address the challenge of large-scale islet cell production, a significant hurdle in the commercialization of islet cell therapies. Lineage intends to establish a production process that supports the entire dynamic culturing system, potentially allowing for widespread therapeutic application. CEO Brian M. Culley highlighted the potential of islet cell transplants to provide a functional cure for some diabetes patients and expressed confidence in achieving feasibility with modest investment. Success in this endeavor could pave the way for licensing opportunities or direct entry into the diabetes market, enhancing the company's position in the field of cell therapy.